Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 3 patents
20 readers on Mendeley
  • Article usage
  • Citations to this article (34)

Advertisement

Research Article Free access | 10.1172/JCI116112

O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b.

J A Carew, S M Quinn, J H Stoddart, and D C Lynch

Laboratory of Neoplastic Disease Mechanisms, Dana-Farber Cancer Institute, Boston, Massachusetts 02115.

Find articles by Carew, J. in: JCI | PubMed | Google Scholar

Laboratory of Neoplastic Disease Mechanisms, Dana-Farber Cancer Institute, Boston, Massachusetts 02115.

Find articles by Quinn, S. in: JCI | PubMed | Google Scholar

Laboratory of Neoplastic Disease Mechanisms, Dana-Farber Cancer Institute, Boston, Massachusetts 02115.

Find articles by Stoddart, J. in: JCI | PubMed | Google Scholar

Laboratory of Neoplastic Disease Mechanisms, Dana-Farber Cancer Institute, Boston, Massachusetts 02115.

Find articles by Lynch, D. in: JCI | PubMed | Google Scholar

Published December 1, 1992 - More info

Published in Volume 90, Issue 6 on December 1, 1992
J Clin Invest. 1992;90(6):2258–2267. https://doi.org/10.1172/JCI116112.
© 1992 The American Society for Clinical Investigation
Published December 1, 1992 - Version history
View PDF
Abstract

By transfecting the full-length cDNA for human von Willebrand factor (vWf) into a line of Chinese hamster ovary cells with a defect in carbohydrate metabolism, we have prepared recombinant vWf specifically lacking O-linked carbohydrates. We have compared this under-glycosylated protein to fully glycosylated recombinant vWf with respect to several structural and binding properties. vWf deficient in O-linked glycans was synthesized, assembled into multimers, and secreted in an apparently normal manner and was not prone to degradation in the extracellular milieu. It did not differ from fully glycosylated vWf in ability to bind to heparin or to collagen type I but did interact less well with glycoprotein 1b on formalin-fixed platelets. This decreased interaction was evidenced in both a lessened overall binding to platelets and in diminished capacity to promote platelet agglutination, in the presence of ristocetin. In contrast, no difference was seen in platelet binding in the presence of botrocetin. These data indicate a possible role for O-linked carbohydrates in the vWf-glycoprotein 1b interaction promoted by ristocetin and suggest that abnormalities in carbohydrate modification might contribute to the altered ristocetin-dependent reactivity between vWf and platelets described for some variant forms of von Willebrand disease.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2258
page 2258
icon of scanned page 2259
page 2259
icon of scanned page 2260
page 2260
icon of scanned page 2261
page 2261
icon of scanned page 2262
page 2262
icon of scanned page 2263
page 2263
icon of scanned page 2264
page 2264
icon of scanned page 2265
page 2265
icon of scanned page 2266
page 2266
icon of scanned page 2267
page 2267
Version history
  • Version 1 (December 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (34)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 3 patents
20 readers on Mendeley
See more details